Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action

Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: Integrative Analysis of Four Double-Blind, Randomized Clinical Trials

(2015) Susan G. Kornstein et al.   CNS SPECTRUMS

Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter

(2011) Brent J. Thompson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Changes in plasma and platelet BDNF levels induced by S-citalopram in major depression

(2011) Montserrat Serra-Millàs et al.   PSYCHOPHARMACOLOGY

Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat

(2010) Yang Zhang et al.   BRAIN RESEARCH

The serotonin transporter gene and risk for alcohol dependence: A meta-analytic review

(2010) R. Kathryn McHugh et al.   DRUG AND ALCOHOL DEPENDENCE

Time-dependent effects of escitalopram on brain derived neurotrophic factor (BDNF) and neuroplasticity related targets in the central nervous system of rats

(2010) Silvia Alboni et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis

(2010) Raymond W. Lam et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Efficacy of escitalopram compared to citalopram: a meta-analysis

(2010) Stuart Montgomery et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Escitalopram Enhances the Association of Serotonin-1A Autoreceptors to Heteroreceptors in Anxiety Disorders

(2010) A. Hahn et al.   JOURNAL OF NEUROSCIENCE

Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression

(2010) Brian Leonard et al.   JOURNAL OF PSYCHOPHARMACOLOGY

What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology

(2010) David J Nutt et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Two Enantiomers of Citalopram Bind to the Human Serotonin Transporter in Reversed Orientations

(2010) Heidi Koldsø et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Serum Concentrations of Citalopram – Dose-Dependent Variation inR- andS-Enantiomer Ratios

(2010) L. Tanum et al.   PHARMACOPSYCHIATRY

Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence

(2010) Leea H. Muhonen et al.   PSYCHIATRY RESEARCH

Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression

(2010) V. Bhagya et al.   PSYCHOPHARMACOLOGY

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat

(2010) Björn Schilström et al.   SYNAPSE

Escitalopram in the treatment of major depressive disorder: A meta-analysis

(2009) Sidney H. Kennedy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges

(2009) Richard Morphy et al.   CURRENT PHARMACEUTICAL DESIGN

Therapeutic Relevance of the Allosteric Modulation of the 5-HT Transporter

(2009) Ouissame Mnie-Filali et al.   Current Signal Transduction Therapy

Superiority of escitalopram to paroxetine in the treatment of depression

(2009) Siegfried Kasper et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action☆

(2009) P.J. Lucassen et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram

(2009) Siegfried Kasper et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

(2009) Stuart A. Montgomery et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Location of the Antidepressant Binding Site in the Serotonin Transporter

(2009) Jacob Andersen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress

(2009) Olaf Schulte-Herbrüggen et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Chronic Treatment with Escitalopram but Not R-Citalopram Translocates G s from Lipid Raft Domains and Potentiates Adenylyl Cyclase: A 5-Hydroxytryptamine Transporter-Independent Action of This Antidepressant Compound

(2009) L. Zhang et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Early-life stress and antidepressant treatment involve synaptic signaling and Erk kinases in a gene-environment model of depression

(2009) Laura Musazzi et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Antidepressant specificity of serotonin transporter suggested by three LeuT–SSRI structures

(2009) Zheng Zhou et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: Kinetic binding studies with the ALI/VFL–SI/TT mutant

(2009) Huailing Zhong et al.   NEUROSCIENCE LETTERS

Neuronal nitric oxide synthase: Structure, subcellular localization, regulation, and clinical implications

(2009) Li Zhou et al.   NITRIC OXIDE-BIOLOGY AND CHEMISTRY

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder

(2009) Andrew F. Leuchter et al.   PSYCHIATRY RESEARCH

Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study

(2009) Andrew F. Leuchter et al.   PSYCHIATRY RESEARCH

Glutamate-based antidepressants: 20 years on

(2009) Phil Skolnick et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

(2008) Darrick T. Balu et al.   BRAIN RESEARCH

Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice

(2008) M Kreilgaard et al.   BRITISH JOURNAL OF PHARMACOLOGY

Driving Forces for Ligand Migration in the Leucine Transporter

(2008) Anne Marie Jørgensen et al.   Chemical Biology & Drug Design

Remodelling by early-life stress of NMDA receptor-dependent synaptic plasticity in a gene–environment rat model of depression

(2008) Ben Ryan et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Postmortem Brain Tissue of Depressed Suicides Reveals Increased Gs  Localization in Lipid Raft Domains Where It Is Less Likely to Activate Adenylyl Cyclase

(2008) R. J. Donati et al.   JOURNAL OF NEUROSCIENCE

Binding of Serotonin to the Human Serotonin Transporter. Molecular Modeling and Experimental Validation

(2008) Leyla Celik et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Escitalopram and Duloxetine in Major Depressive Disorder

(2008) Alan G Wade et al.   PHARMACOECONOMICS

Going with the Flow: Trafficking-Dependent and -Independent Regulation of Serotonin Transport

(2008) Jennifer A. Steiner et al.   TRAFFIC

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model

(2007) Qi Peng et al.   EXPERIMENTAL NEUROLOGY